Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03226522 · ClinicalTrials.gov registry record · Phase 2
Addressing Dementia Via Agitation-Centered Evaluation
A Phase 2 study, sponsored by Axsome Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 366
- Enrollment target
NCT03226522 is a Phase 2 study that has completed, run by Axsome Therapeutics. The registered enrollment target is 366 participants.
The verdict
NCT03226522, a Phase 2 study, has completed, sponsored by Axsome Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 366 participants
- Enrollment target
Study Summary
This is a multi-center, randomized, double-blind, placebo-controlled study, to assess the efficacy and safety of AXS-05 in the treatment of agitation in patients with Alzheimer's disease.
Interventions
- DRUG Placebo
- DRUG AXS-05
- DRUG Bupropion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 366 participants |
| Start Date | 2017-07-13 |
| Est. Completion | 2020-04-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03226522
The ClinicalTrials.gov registry entry for NCT03226522 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 366 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Axsome Therapeutics, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03226522 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03226522 about?
NCT03226522 is a clinical study titled "Addressing Dementia Via Agitation-Centered Evaluation". This is a multi-center, randomized, double-blind, placebo-controlled study, to assess the efficacy and safety of AXS-05 in the treatment of agitation in patients with Alzheimer's disease.
What is the current status of trial NCT03226522?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 366 participants. The study started on 2017-07-13. Estimated completion is 2020-04-17.
What interventions are being tested in trial NCT03226522?
The interventions under investigation include: Placebo (DRUG), AXS-05 (DRUG), Bupropion (DRUG).
Who is sponsoring clinical trial NCT03226522?
This trial is sponsored by Axsome Therapeutics, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.